finance
Session Initiation positive for the major European stock markets, after a good session scored by Wall Streett last night. But Europe this morning seems to also take advantage of the pause that today’s markets the U.S. compared to holidays. In sharp rise in the stock market opened with the Paris Cac 40, which marks +1.82% to 3689 points. Out in front of Frankfurt’s DAX 30 marks +1.73% to 4209 points.
The scholarships are trapped in the dark tunnel of the crisis and one of the first areas that continues to pick up the bill is that of luxury. Added to this is that it is the economic crisis in Japan and the fear of attacks, which reduced the tourist trips, weigh on the accounts of companies in the sector. So today, the title Tod’s leaves at ground level from 3.33%, dropping below 45 euros. Tod’s is trading at 44.9 euros.
There seems to have the strength to recover the price of technological Piazza Affari. The Numtel is in fact registered a decline of 0.6% due to a false start of On Bank (-3.7%), BB Biotech (-3.2%), Finmatica (-1%) and Tiscali (-1% ). Continues, however, interest in Vitaminic that has been suspended for excessive upward at 15.70 euros. Even yesterday Vitaminic has been suspended for almost the entire session. The company has denied any operation on capital.
does not stop the enthusiasm of the Milan Stock for Italgas that is touching new high. The title of the company led by Alberto Meomartini is in fact going up 5.45% of the testing fee 11.85 euro after a maximum intraday 11.95 euros. Very high trade: 8.5 million units compared to an average of 1.4 million. Italgas benefits of resolution dell’Autority Energy, which changed the mechanisms for setting tariffs for local gas distribution companies taking over the Tar signs of Lombardy.
Analysts at Morgan Stanley judge still attractive to the oil sector. “We believe that economic recovery will lead the growth of oil demand, and therefore at least the stability of oil prices over the next two years,” they hear from the merchant bank. Among the different titles is interesting to Saipem. The study highlighted how it has been slightly polished the expectation of EPS Saipem 2002, which rose from 0.44 to 0.43 euros, but is instead increased the estimate for 2003 from 0.43 to 0.52 euros. Morgan Stanley expects profits for Saipem 2002-190 million euros against 168 million in 2001, which then rise to 231 million euros in 2003. Aumeteranno the income from 1.927 billion euros in 2001-2780 million for 2002 and 3.502 million in 2003.
Party on the right foot on Numtel (+2.79%) who benefits from good session yesterday on the Nasdaq. New Market on the list of outstanding performances of e.Biscom (+4.14%) to 29.70 euros, thanks to the words of the AD Silvio Scaglia said that as the results of Fastweb in the second quarter are excellent, but also of Tiscali (+2.1%) to 6.14 euros. Well even AISOFTW (+5.4%), Biosearch (+4%), Gandalf (+9%). Red instead Euphon (-4%).
No peace for the two companies related to the construction industry. Impregilo is in fact losing 7% with the title which is the said to 0.46 euros while Astaldi is leaving the ground on 6.36% to 2.445 euro, new low. Be noted that Impregilo has lost more than 30% in less than a month because, say some traders, exposure in Brazil. Astaldi instead lost 21% since his debut (3.10 € ndr.).
ABN Amro has lowered its recommendation on the title of France Telecom, bringing it from buy to hold, and indicating a price target to 16 euros. For analysts the bank’s Dutch business, FT following the downgrade by Moody’s has strong liquidity and fill necesita to recover his debt. So a new share issues seems inevitable. A reduction in the cash gap, emphasizes ABN Amro, reassure the market and may have beneficial effects throughout the industry. Also, added the analysts, the French telecoms operator needs to resolve as soon as his battle with MobilCom. At this moment the title FT is accusing a loss of 13.96% Bulgarian dragging the share price to 9.12 euros.
Do not save even the pharmaceutical sales wave that is sweeping all the lists of Europe. All major sector securities exchange in negative territory and the most disadvantaged are Sanofi-Synthelabo (-5.03%), Aventis (-3.64%), Novo Nordisk (-3.01%), GlaxoSmithKline (-2.77 %), Roche Holding (-2.72%), Shire Pharmaceuticals (-2.70%), Shering (-2.56%), Novartis (-2.47%) and AstraZeneca (-2.21%).
